Centivax, developer of a universal flu and other vaccines, has raised $37 million in follow-on funding, CEO Jake Glanville tells Axios Pro exclusively.
Why it matters: It's a challenging time to build a vaccine company, experts have told Axios Pro, as the current FDA has created hurdles for some firms.
